...
首页> 外文期刊>Pharmaceutical development and technology >Formulation and development of taste masked fast-disintegrating tablets (FDTs) of Chlorpheniramine maleate using ion-exchange resins.
【24h】

Formulation and development of taste masked fast-disintegrating tablets (FDTs) of Chlorpheniramine maleate using ion-exchange resins.

机译:使用离子交换树脂配制和掩盖马来酸氯苯那敏的掩味速崩片(FDT)。

获取原文
获取原文并翻译 | 示例

摘要

Masking of bitter taste of drug for better patient compliance.The objective of this research was to mask the bitter taste of Chlorpheniramine maleate using cation exchange resins.Different cation exchange resins were used for taste masking. The drug resin complexes (DRC) were prepared by batch process. Complexes of ion-exchange resin and Chlorpheniramine maleate were prepared by taking drug: resin ratios 1:1, 1:2, 1:3 and 1:4 (w/w). The optimum drug:resin ratio and the time required for maximum complexation was determined. The drug resinates were evaluated for the drug content, taste, drug release, FTIR, DSC and X-ray diffraction (PXRD).The X-ray diffraction study confirmed the monomolecularity of entrapped drug in the resin beads. The taste evaluation depicted the successful taste masking of Chlorpheniramine maleate with DRCs. Fast disintegrating tablets (FDTs) were developed depending upon percent complexation, release study at salivary and gastric pH, taste evaluation; Chlorpheniramine maleate: Indion-234 complex of ratio 1:2 was used to develop and formulate FDTs. The drug release of 94.77% in 30?min was observed from FDTs.The Effective taste masking can be obtained from DRC that can be formulated as FDTs for better patient compliance.
机译:掩盖药物的苦味以更好地满足患者的需求。本研究的目的是使用阳离子交换树脂掩盖马来酸氯苯那敏的苦味。使用不同的阳离子交换树脂掩盖味道。药物树脂复合物(DRC)是通过分批工艺制备的。离子交换树脂与马来酸氯苯那敏的复合物是通过采用药物与树脂的比例1:1、1:2、1:3和1:4(w / w)制备的。确定了最佳的药物:树脂比例和最大络合所需的时间。对药物树脂酸酯进行了药物含量,味道,药物释放,FTIR,DSC和X射线衍射(PXRD)评估。X射线衍射研究证实了树脂珠中截留的药物具有单分子性。味道评估表明,用DRC成功掩盖了马来酸氯苯那敏。根据络合百分比,唾液和胃液pH值的释放研究,味觉评估,开发了快速崩解片(FDT)。比例为1:2的马来酸氯苯那敏:Indion-234复合物用于开发和配制FDT。从FDTs中观察到在30分钟内药物释放率为94.77%。可从DRC获得有效的掩味作用,可将其配制为FDTs,以更好地使患者依从性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号